Evidence map›Paper›PMID 17211541›Full record

ArticleCurrent microbiology2007

Cytoprotective agent in Lactobacillus bulgaricus extracts.

Paul Johns, Suzette L Pereira, Amanda E Leonard, Pradip Mukerji, Robert A Shalwitz, Lobat Dowlati, Rosalyn R Phillips, Marti S Bergana, Jason D Holton, Tapas Das

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Paul JohnsAbbott Laboratories, Ross Products Division, Columbus, Ohio 43219, USA. paul.johns@abbott.com
Suzette L Pereira
Amanda E Leonard
Pradip Mukerji
Robert A Shalwitz
Lobat Dowlati
Rosalyn R Phillips
Marti S Bergana
Jason D Holton
Tapas Das
Ross Laboratories (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenosine 5'-diphosphoribose (ADP-ribose) has been identified as a significant contributor to the anti-cytotoxic activity of Lactobacillus bulgaricus extracts. Although the biological activities associated with the administration of probiotic bacteria and components thereof are sometimes attributed to the peptidoglycans that comprise a substantial portion of the Gram-positive bacterial cell wall, we found that the beta-nicotine adenine dinucleotide (NAD) hydrolysis product ADP-ribose was a significant contributor to the observed anti-cytotoxicity in our L. bulgaricus extracts. The ADP-ribose was isolated, identified, and quantitated by high performance liquid chromatography (HPLC) and by nuclear magnetic resonance (NMR) spectroscopy. ADP-ribose levels as low as 5 mg/L exhibited a measurable inhibition of tumor necrosis factor alpha (TNF-alpha) mediated cytotoxicity in an in vitro cell assay, whereas the ADP-ribose content of the L. bulgaricus extracts often exceeded 5 mg/g dry weight.

Indexed as

Adenosine Diphosphate RiboseCell LineChromatography, High Pressure LiquidCycloheximideEpithelial CellsLactobacillusLungMagnetic Resonance SpectroscopyProbioticsTumor Necrosis Factor-alphaAdenosine Diphosphate RiboseCycloheximideTumor Necrosis Factor-alpha

Identifiers

PMID17211541
OpenAlexW2052414073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.